Related Blog Posts from the Wikinvest Wire

Pfizer (PFE)   Subscribe to Pfizer (PFE) content from the Wikinvest Wire
 » Back to Pfizer (NYSE:PFE) Stock Page

  

7/25/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Ltd’s Profit from operations before other inco... (Jutia Group)

[at noodls] - NEWS RELEASE Pfizer Ltd's Profit from operations before other income, finance cost and tax for the Quarter increased by 40% Pfizer Ltd announced the results for the first quarter ended June 30, 2014. The ... Read more on this. Pfizer Inc. (PFE), currently valued at $192.80B, started the session at [...]

7/16/14Stock Update (NYSE:PFE): Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG... (Jutia Group)

[at noodls] - Once-Weekly Prophylaxis Treatment with BeneFIX® Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Treatment "Pfizer remains committed to the research and development of new and ... Read more on this. Pfizer Inc. (PFE), with a current market cap of $193.98B, began trading this morning at $30.22.   [...]

6/18/14Pfizer Inc (NYSE:PFE) – French biotech Cellectis surges as Pfizer signs cancer drug deal (Jutia Group)

[Reuters] - * Pfizer secures access to early cancer-hunting CAR-T drugs * Cellectis gets $80 mln upfront, shares soar 50 percent (Adds details on rival Novartis research, more on technology, Cellectis valuation) June 18 (Reuters) - U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca , said on [...]

6/17/14Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Submission of Biologics License Applica... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for bivalent recombinant LP2086 (r Read more on this. Pfizer Inc. (PFE), valued at $188.87B, opened at $29.50.   Looking at today's market, PFE one day range is [...]

6/13/14Pfizer Inc (NYSE:PFE) | Drug-linked payouts: complex fix for Pfizer’s next Astra bid? (Jutia Group)

[Reuters] - The world's biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal a deal with AstraZeneca remains intense. Even as talks fell apart last month, some in Pfizer's camp remained optimistic the transaction could be revived - and certain AstraZeneca advisers have not [...]

5/27/14 (Jutia Group)

[Business Wire] - Pfizer Inc. today announced the introduction in the U.S. of over-the-counter Nexium® 24HR, making The Purple Pill® available for the treatment of frequent heartburn in adults . Read more on this. Pfizer Inc. (PFE), with a current value of $189.93B, finished yesterday at $29.49.   Looking at [...]

5/26/14Market Update: Pfizer Inc (NYSE:PFE) – Pfizer walks away from $118 bln AstraZeneca takeover fight (Jutia Group)

[Reuters - UK Focus] - * Pfizer (NYSE: PFE - news) can return in 6 months, or 3 months if invited back (Adds AstraZeneca reaction) LONDON/NEW YORK (Frankfurt: HX6.F - news) , May 26 (Reuters) - Pfizer abandoned its attempt to buy AstraZeneca (NYSE: AZN - news) for nearly 70 billion pounds ($118 billion) [...]

5/23/14Company Update (NYSE:PFE): Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today detailed results from the Oral treatment Psoriasis Trial Retreatment study , a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. Read more on this. Pfizer Inc. (PFE), valued at $188.75B, began trading this morning at $29.60.   [...]

5/22/14Pfizer Inc (NYSE:PFE) – BlackRock wants new Astra-Pfizer talks at later date-sources (Jutia Group)

[Reuters - UK Focus] - BlackRock Inc, AstraZeneca Plc's largest shareholder, wants the drugmaker to resume talks with Pfizer Inc about a potential sale eventually, but backs its decision this week to reject Pfizer's current ... Read more on this. Pfizer Inc. (PFE), with a current value of $189.19B, began trading this morning [...]

5/20/14Company Update: Pfizer Inc (NYSE:PFE) – Schroders, Fidelity reveal investor split as Astra reje... (Jutia Group)

[Reuters] - Schroders said on Tuesday it was disappointed with "the quick rejection by the AstraZeneca board" of an improved 55 pounds-a-share offer and the decision by Pfizer to "draw a premature end to these negotiations by calling their latest proposal final". "Given the increase in the offer we would encourage the AstraZeneca management [...]

5/16/14Company Update (NYSE:PFE): Pfizer To Submit Palbociclib New Drug Application With FDA Based On Fi... (Jutia Group)

[Business Wire] - Pfizer Inc. today announced that it will submit a New Drug Application with the United States Food and Drug Administration for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. Read [...]

5/15/14Stock Update (NYSE:PFE): Pfizer move on Astra threatens UK science, lawmakers say (Jutia Group)

[Reuters] - Pfizer's (PFE) potential takeover of AstraZeneca (AZN.L) poses a threat to British science unless the U.S. drugmaker can give more concrete, enforceable guarantees on jobs and investment, politicians scrutinizing the deal said on Thursday. London-based AstraZeneca has rejected a $106 billion offer from Pfizer and expressed concern that Pfizer would shut down [...]

5/14/14Company Update: Pfizer Inc (NYSE:PFE) – UK lawmaker stirs political row with Pfizer "rapist" co... (Jutia Group)

[Reuters - UK Focus] - A lawmaker from Britain's opposition Labour party stirred a political row on Wednesday after describing U.S. drugmakers Pfizer as "rapists" in comments criticising the government for its handling ... Read more on this. Pfizer Inc. (PFE), currently valued at $186.32B, opened this morning at $29.14.   [...]

5/13/14Pfizer Inc (NYSE:PFE) – UK minister says intervention on AstraZeneca, Pfizer "tricky" (Jutia Group)

[Reuters - UK Focus] - Intervening in Pfizer's proposed acquisition of AstraZeneca using public interest rules is "quite tricky" and could be a lengthy process, British business minister Vince Cable said on Tuesday. ... Read more on this. Pfizer Inc. (PFE), currently valued at $186.70B, started the session at $29.14.   [...]

5/12/14Market Update (NYSE:PFE): Pfizer tightens levels by 10bp-20bp at guidance (Jutia Group)

[Reuters - UK Focus] - NEW YORK (Frankfurt: HX6.F - news) , May 12 (IFR) - Pfizer Inc (NYSE: PFE - news) tightened pricing levels at the guidance stage Monday on its latest multi-part dollar bond by about 10bp to 20bp across the curve. The company, which is currently looking to acquire AstraZeneca (NYSE: [...]

5/9/14Pfizer Inc (NYSE:PFE) – Pfizer Announces Positive Phase 2 Study Results for Investigational Men... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. Read more on this. Pfizer Inc. (PFE), with a current [...]

5/8/14Company Update: Pfizer Inc (NYSE:PFE) – Fitch Solutions: CDS Sentiment Souring for Pfizer, Impr... (Jutia Group)

[Reuters] - Takeover speculation involving AstraZeneca Plc and Pfizer is leading to two very different sentiments with respect to credit default swap (CDS) spread movement, according to Fitch Solutions in its latest CDS case study snapshot. While five-year CDS on AstraZeneca have tightened 21% in the past month, Pfizer's CDS have widened 28%. 'Credit [...]

5/7/14Market Update: Pfizer Inc (NYSE:PFE) – AstraZeneca in partnering talks for Alzheimer’s drug (Jutia Group)

[Reuters - UK Focus] - * AstraZeneca (NYSE: AZN - news) ready to start Phase III tests on BACE drug (Adds quote, details on competitors, background) LONDON, May 7 (Reuters) - AstraZeneca, fighting a $106 billion bid approach from Pfizer (NYSE: PFE - news) , is talking to other companies as it seeks a [...]

5/6/14Company Update (NYSE:PFE): Second UK lawmaker panel to call Pfizer, AstraZeneca over bid (Jutia Group)

[Reuters - UK Focus] - Senior management from U.S. drugmaker Pfizer (NYSE: PFE - news) and British pharmaceutical firm AstraZeneca (NYSE: AZN - news) will be called before a British parliamentary committee to answer questions on a potential takeover deal, the committee chairman said on Tuesday. AstraZeneca on Friday rejected a 63 billion-pound ($106.26 [...]

5/5/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer’s (PFE) CEO Ian Read on Q1 2014 Results – Ea... (Jutia Group)

[Seeking Alpha] - Good day, everyone and welcome to Pfizer's First Quarter 2014 Earnings Conference Call. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Good morning and thank you for joining us today to review Pfizer's first quarter 2014 performance. Read [...]

5/2/14Market Update: Pfizer Inc (NYSE:PFE) – AstraZeneca rejects Pfizer’s raised bid of $106 bln (Jutia Group)

[Reuters - UK Focus] - U.S. drugmaker Pfizer Inc increased its offer for AstraZeneca Plc to 63 billion pounds on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals ... Read more on this. Pfizer Inc. (PFE), valued at $196.08B, opened at $31.06.   [...]

5/1/14Market Update (NYSE:PFE): Pfizer prepares sweeter bid for AstraZeneca – report (Jutia Group)

[Reuters - UK Focus] - Pfizer Inc may sweeten its offer for Britain's AstraZeneca Plc to more than 63 billion pounds, or $106 billion, and raise the cash portion of the deal, to kickstart negotiations, Bloomberg reported on ... Read more on this. Pfizer Inc. (PFE), currently valued at $198.70B, opened at $31.09. [...]

4/30/14Pfizer Inc (NYSE:PFE) | UK lawmakers plan to probe Pfizer pursuit of AstraZeneca (Jutia Group)

[Reuters - UK Focus] - * Lawmakers want to protect research and jobs in UK * Planned $100 bln bid would be biggest ever of a UK firm * Pfizer (NYSE: PFE - news) unable to commit on jobs or investment (Adds comment on timing, witnesses) LONDON, April 30 (Reuters) - British lawmakers intend [...]

4/29/14Company Update (NYSE:PFE): Fitch: Pfizer, AstraZeneca Combo Would Achieve Strategic Aims (Jutia Group)

[Reuters - UK Focus] - The acquisition of AstraZeneca Plc (NYSE: AZN - news) (AZ) would achieve Pfizer (NYSE: PFE - news) , Inc.'s strategic aims as the deal promises significant benefits for the combined entity, according to Fitch Ratings. The transaction would amass scale for Pfizer, broaden the company's portfolio and pipeline and [...]

4/28/14Pfizer Inc (NYSE:PFE) – Pfizer chasing AstraZeneca for potential $100 bln deal (Jutia Group)

[Reuters - UK Focus] - U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion battle for Britain's AstraZeneca Plc after having two bids rejected, as deal-making grips the healthcare industry. Pfizer ... Read more on this. Pfizer Inc. (PFE), valued at $201.92B, opened this morning at $31.59. [...]

4/25/14Stock Update: Pfizer Inc (NYSE:PFE) – AstraZeneca bid talk "a commercial matter" -UK finance mi... (Jutia Group)

[Reuters - UK Focus] - CAMBRIDGE (SES: E1:J91U.SI - news) , England, April 25 (Reuters) - Talk of a $100 billion bid by U.S. drugmaker Pfizer (NYSE: PFE - news) for its British rival AstraZeneca (NYSE: AZN - news) is "a commercial matter between the companies", Britain's finance minister George Osborne said on Friday. [...]

4/24/14Pfizer Inc (NYSE:PFE) – Pfizer Hosts Annual Meeting of Shareholders Declares 26-Cent Second-Qua... (Jutia Group)

[Business Wire] - The board of directors of Pfizer Inc. today declared a 26-cent second-quarter 2014 dividend on the company’s common stock, payable June 3, 2014, to shareholders of record at the close of business on May 9, 2014. Read more on this. Pfizer Inc. (PFE), valued at $195.45B, opened this morning at [...]

4/22/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Positive Top-Line Results from Two Pha... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials Program, OPT Pivotal #1 and OPT Pivotal #2 , evaluating the efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, the first in a new class of medicines being investigated for the [...]

4/21/14Company Update (NYSE:PFE): Promotional Campaigns, Equity Awards, Stock Price Movements, New Launc... (Jutia Group)

[PR Newswire] - Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (PFE), Intuitive Surgical, Inc. (ISRG), HCA Holdings Inc. (HCA), General Electric Company (GE) and Deere & Company (DE). On April 14, 2014, Pfizer Inc. (Pfizer) announced that Pfizer Consumer Healthcare is teaming up with actor and active volunteer Josh Duhamel for [...]

4/18/14Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to Listen to Webcast of April 24 Annual Meeting o... (Jutia Group)

[Business Wire] - Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. on Thursday, April 24. To acc Read more on this. Pfizer Inc. (PFE), currently valued at $193.08B, started the session at $30.19.   Looking at [...]

4/17/14Company Update: Pfizer Inc (NYSE:PFE) – Teva settles patent suit with Pfizer over Celebrex (Jutia Group)

[Reuters] - Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. A U.S. court in March invalidated a patent extending Pfizer's marketing exclusivity for Celebrex to Dec. 2, 2015. Celebrex's basic chemical patent is set to expire this [...]

3/26/14Company Update (NYSE:PFE): Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GEN... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN® on the height in small-for-gestational-age children 24-30 months old. Read more on this. Pfizer Inc. (PFE), with a current market cap of $206.42B, opened at $31.97.   During today's [...]

3/25/14Pfizer Inc (NYSE:PFE) | Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference C... (Jutia Group)

[Business Wire] - Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Monday, May 5, 2014. The purpos Read more on this. Pfizer Inc. (PFE), with a current market cap of $203.10B, opened at $31.77. [...]

3/18/14Market Update (NYSE:PFE): Pfizer Launches 2013 Integrated Annual Review (Jutia Group)

[Business Wire] - Pfizer Inc. today announced the launch of its fourth integrated annual review , which summarizes the company’s 2013 financial, environmental and s Read more on this. Pfizer Inc. (PFE), currently valued at $203.62B, opened at $31.47.   A quick look at the market, the company's traded between [...]

3/12/14Pfizer Inc (NYSE:PFE) – Pfizer Announces Webcast Of April 6 Conference Call With Securities Ana... (Jutia Group)

[Business Wire] - Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s Oncology leadership on Sunday, April 6, 2014 at 1:30 p.m. Pacific Daylight Time, in connection with the presentation of the final results of the PALOMA-1 Phase 2 trial for palbociclib at [...]

3/5/14 (Jutia Group)

[PR Newswire] - Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (PFE), Dendreon Corp. (DNDN), DepoMed Inc. (DEPO), Globus Medical, Inc. (GMED), and Array BioPharma, Inc. (ARRY). On March 3, 2014, Pfizer Inc.'s (Pfizer) stock decreased 0.40% to end the day at $31.98, compared to the previous day's closing price at $32.11. [...]

2/24/14Pfizer Inc (NYSE:PFE) – Pfizer Announces FDA Approval to Include Radiographic Data on Reduction... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a supplemental New Drug Application to update the current label of XELJANZ® 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan and ORAL Start . Read more on this. Pfizer Inc. (PFE), [...]

2/21/14Pfizer Inc (NYSE:PFE) – In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and D... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular [...]

2/18/14Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to View and Listen to Webcast of Pf... (Jutia Group)

[Business Wire] - Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 8:50 a.m. Read more on this. Pfizer Inc. (PFE), currently valued [...]

2/14/14Stock Update: Pfizer Inc (NYSE:PFE) – Behind Pfizer’s latest upheaval at the top (Jutia Group)

[at Fortune] - FORTUNE -- Amy Schulman, one of Pfizer's (PFE) star execs and No. 43 on the Fortune Most Powerful Women list, is out of a job. And the irony is that her dismissal comes just as she expected to vault into ... Read more on this. Pfizer Inc. (PFE), with a [...]

2/11/14Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer Statement on Today’s Joint Meeting of FDA Adviso... (Jutia Group)

[Business Wire] - Pfizer agrees with the recommendation of the joint meeting of the FDA Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee that the available data do Read more on this. Pfizer Inc. (PFE), with a current market cap of $206.55B, opened at $31.79.   Today, [...]

2/7/14Stock Update: Pfizer Inc (NYSE:PFE) – Will These Two Drugs Turn Around Losses at Pfizer? (Jutia Group)

[at Motley Fool] - Pfizer is working on an experimental drug for breast cancer and expanding use of a pneumonia vaccine to offset losses from patent expirations. Read more on this. Pfizer Inc. (PFE), valued at $202.08B, opened at $30.84.   Looking at the stock, its one day range is [...]

2/6/14Stock Update: Pfizer Inc (NYSE:PFE) – March 14th Options Now Available For Pfizer (PFE) (Jutia Group)

[at TheStreet] - Investors in Pfizer Inc saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options chain for the new ... Read more on this. Pfizer Inc. (PFE), currently valued at $199.75B, opened this morning at [...]

2/4/14Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer Among Drugmakers in U.S. Chronic Diseae Project (Jutia Group)

[at Bloomberg] - Pfizer Inc. (PFE) , Eli Lilly & Co. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis. Data generated from the work will be made public for other scientists to use, a move [...]

2/3/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer’s new breast cancer drug succeeds in trial (Jutia Group)

[Reuters] - Pfizer Inc's experimental breast cancer drug significantly improved patient survival rates in a mid-stage trial without their condition worsening, maintaining the company's lead in the race for a new treatment standard for the disease. The oral drug, palbociclib, is considered one of Pfizer's most valuable products in development. Palbociclib was designated a [...]

1/28/14Pfizer Inc (NYSE:PFE) | Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 F... (Jutia Group)

[Business Wire] - Pfizer Inc. reported financial results for fourth-quarter and full-year 2013. As a result of the full disposition of Zoetis on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued operation in the consolidated statements of income for full-year 2013, and fourth-quarter and full-year 2012. [...]

1/27/14Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer lung cancer drug fails in two large studies (Jutia Group)

[Reuters - UK Focus] - Pfizer Inc on Monday said one of its experimental drugs had failed to meet its goals in two late-stage studies among patients who had received prior treatment for advanced non-small cell lung cancer, the ... Read more on this. Pfizer Inc. (PFE), with a current market cap of [...]

1/23/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Earnings Preview: Cost-Cutting To Offset Patent ... (Jutia Group)

[at Forbes] - In terms of therapeutic areas, we expect cancer drugs to do well, as the pressure on cardiovascular sales continues. Geographically speaking, emerging markets will be in focus due to the expected volume growth driven by sales of Prevenar. Read more on this. Pfizer Inc. (PFE), with a current market cap [...]

1/22/14Pfizer Inc (NYSE:PFE) – What to Look for When Pfizer Inc. Reports Earnings (Jutia Group)

[at Motley Fool] - Pfizer's upcoming earnings call is likely to be followed by a wave of commotion. Here are some key factors you can listen in for to draw your own opinion. Read more on this. Pfizer Inc. (PFE), with a current market cap of $202.66B, opened at $31.31.   [...]

1/21/14Pfizer Inc (NYSE:PFE) | Correction: Pfizer likely to report strong trial results, says BMO Capital (Jutia Group)

[theflyonthewall.com] - BMO Capital believes that the results of trials of Pfizer's CAPITA and PALOMA-1 drugs are very likely to be positive. The firm recommends buying the stock ahead of clinical results of trials of the drugs. ... Read more on this. Pfizer Inc. (PFE), valued at $202.60B, ended session yesterday at $31.09. [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki